Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

View All Documentation

919411

Sigma-Aldrich

CCW16-C6-BocNH

Szinonimák:

tert-Butyl (6-(4-(4-(N-benzyl-2-chloroacetamido)phenoxy)phenoxy)hexyl)carbamate, Crosslinker-E3 Ligase ligand conjugate, Protein degrader building block for PROTAC® research, RNF4-targeting building block, Template for synthesis of targeted protein degrader

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)

About This Item

Tapasztalati képlet (Hill-képlet):
C32H39ClN2O5
Molekulatömeg:
567.12
NACRES:
NA.22

ligand

CCW16

Minőségi szint

100

form

viscous liquid

reakcióalkalmasság

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

funkcionális csoport

amine

tárolási hőmérséklet

2-8°C

SMILES string

O=C(CCl)N(CC1=CC=CC=C1)C2=CC=C(C=C2)OC3=CC=C(OCCCCCCNC(OC(C)(C)C)=O)C=C3

Related Categories

Alkalmazás

Protein degrader building block CCW16-C6-BocNH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a RING finger protein 4 (RNF4)-recruiting ligand, an alkyl-chain crosslinker, and a pendant amine for reactivity with a carboxylic acid on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a pendant amine, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Egyéb megjegyzések

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Jogi információk

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

kapcsolódó termék

Product No.
Leírás
Árazás

901496

Pomalidomide-C6-CO2H, ≥98%

901534

(S,R,S)-AHPC-C6-CO2H hydrochloride

911666

Pomalidomide-C6-NH2 hydrochloride, ≥95%

911712

C5 Lenalidomine-C6-NH2 hydrochloride, ≥95%

917931

A1V2PF2-NHEt-C6-NH2

917966

BocA1V2PF1-NHC6-NH2

916927

BocA1V1PF2-OC6-NH2 hydrochloride, ≥95%

916943

A1V2PF1-NHEt-C6-NH2

917427

A1V1PF2-OEt-C6-NH2 hydrochloride

917443

BocA1V2PF2-NHC6-NH2

919438

CCW16-C9-BocNH, ≥95%

919470

CCW16-PEG2-butyl-BocNH, ≥95%

919462

CCW16-PEG5-BocNH, ≥95%

919454

CCW16-PEG3-BocNH, ≥95%

919403

CCW16-C4-BocNH, 95%

919446

CCW16-PEG1-BocNH

919489

CCW16-C6-PEG3-butyl-BocNH

919381

CCW16, ≥95%

Tárolási osztály kódja

10 - Combustible liquids

Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Sajnos jelenleg COA nem áll rendelkezésre ehhez a termékhez online.

Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Carl C Ward et al.
ACS chemical biology, 14(11), 2430-2440 (2019-05-07)
Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Cikkek

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással